Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The current study was designed to investigate which of the inflammasome complexes are critical for IL-1β production in AD.
|
31715312 |
2020 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the current study, we determined the effects of Ampelopsin (AMP) on the levels of proinflammatory cytokines (PICs, IL-1β, IL-6 and TNF-α), and products of oxidative stress 8-isoprostaglandin F2α (8-iso PGF2α, a product of oxidative stress); and 8-hydroxy-2'-deoxyguanosine (8-OHdG, a key biomarker of protein oxidation) in the hippocampus using a rat model of AD.
|
31797758 |
2020 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interleukin-1β is a potent proinflammatory cytokine that plays a key role in the pathogenesis of the brain aging and diverse range of neurological diseases including Alzheimer's disease, Parkinson's disease, stroke and persistent pain.
|
31535638 |
2020 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the current report, we determined the effects of microRNA-155 (miR-155) on the levels of IL-1β, IL-6 and TNF-α, and their respective receptors in the hippocampus using a rat model of AD.
|
31456514 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
CCH strongly enhanced NLRP3, activated caspase-1 and IL-1β expressions in hippocampus and thalamus at age 12 M of AD mice.
|
29885344 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control.
|
30630955 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, apelin-13 inhibited microglia and astrocyte activation, reduced IL-1β and TNF-α expression and hippocampal BDNF/TrkB expression deficit in AD rats.
|
31040784 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study measured amyloid-beta (Aβ), interleukin-1 beta (IL-1β), and glial fibrillary acidic protein (GFAP) expression in the hippocampus of Alzheimer's disease (AD) rat models to elucidate the mechanism of anti-inflammatory effect of ginsenoside Rb1 in AD.
|
31217866 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, THS reduced mRNA expression of the proinflammatory cytokines, TNF-α, IL-6, and IL-1β and increased synapse-associated proteins (synaptophysin and postsynaptic density protein 95) in the hippocampus of AD mice.
|
31244052 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The db mutation also reduced the cortical IL-1β mRNA level and IBA1 protein level in young AD mice, with no significant effect on the activation of microglia and astrocytes.
|
31034991 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Defects in interleukin-1β (IL-1β)-mediated cellular responses contribute to Alzheimer's disease (AD).
|
31570577 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the AD model group, the inhibition of PC12 cell growth was significantly increased, and the mRNA expression levels of IL‑1β, IL‑6, TNF‑α and MIF were also increased.
|
31322215 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of IL-1β and iron accumulation have been identified in microglial cells that cluster around amyloid plaques in AD mouse models and post-mortem brain tissues of AD patients.
|
31693761 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our data showed that SEO improved the cognitive ability of mice with Aβ<sub>1-42</sub> or lipopolysaccharides (LPS)-induced Alzheimer's disease (AD) and suppressed the production of tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in the hippocampus.
|
31463498 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, a significant increased expression of cleaved caspase-1 and IL-1β, the products of inflammasome activation, was detected in the cortex of AD brains.
|
30741672 |
2019 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
However, the lack of P2X7R did not significantly affect the release of IL-1β or the levels of non-amyloidogenic fragment, sAPPα, in AD mice.
|
29934546 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Increased concentrations of interleukin 1 (IL-1) in the cerebrospinal fluid and serum of patients with Alzheimer disease (AD) reduced phagocytic capacity point to an inflammatory activation of mononuclear phagocytes in AD.
|
31018751 |
2019 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared with controls, IL-1β (pooled SMD: 1.37, 95% CI: 0.06-2.68, significant heterogeneity: I<sup>2</sup> = 96.01%) was significantly elevated in Alzheimer's disease.
|
30104698 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Importantly, CTSB activity, IL-1β levels and malondialdehyde (MDA) were remarkably elevated in plasma of AD patients compared to healthy controls, while glutathione was significantly lower than healthy controls.
|
29196167 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Brain inflammation including increases in inflammatory cytokines such as IL-1β is widely believed to contribute to the pathophysiology of Alzheimer's disease.
|
29712570 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The results showed that the hippocampal and serum levels of ROS, nitrite, TNF-α, and IL-1β were significantly higher in the AD animals along with increased chromatolysis and impairments of memory.
|
30377887 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings support the clinical development of Mcc950 and clinically available IL-1- and TNF-α-neutralizing agents in early AD.
|
29477641 |
2018 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Increased inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1β (IL-1 β), and tumor necrosis factor-α (TNF-α) are associated with Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).
|
28856541 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we studied the effect of amyloid beta-peptides (Aβ), interleukin 1-beta (IL-1β), and CSF from AD, Lewy body dementia (LBD) or subjective cognitive impairment (SCI) patients on the NGF overproducing cell line NGC-0295.
|
30092220 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Circulating levels of IL-1 family cytokines and receptors in Alzheimer's disease: new markers of disease progression?
|
30541566 |
2018 |